22UA Stock Price and Chart — XETR:22UA — TradingView

Compare with BioNTech SE Sponsored ADR

Key stats

Upcoming earnings

Details

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Financials

Performance

Revenue to profit conversion

Debt level and coverage

Earnings

Next:—

Ideas

BioNTech (BNTX) LONG — 4H ALMA Setup (WR 80%)█ SETUP NASDAQ:BNTX · 4H · long only. (Context: BioNTech — mRNA platform; oncology pivot post-COVID; Pfizer Comirnaty partner.) ALMA Averaging Strategy: ALMA 3 / σ2, SD band 2, min diff 6/1, 25% per bar, up to 4 adds, hard stop −10% from average entry. Strategy Tester (BNTX 4H): Win rate 80

by Goldfinch_song

Smart money has been buying in advance of a pandemic The SMC compression pattern is a bottoming reversal pattern. During this phase, smart money engineers liquidity and buys stock prior to a violent markup phase. It's seeming quite likely that the accumulation phase is over and now we've also got the hantavirus catalyst, so a sharp re-rating of the st

06:54

by markethunter888

BioNTech Price Target Cut at Citi Following Co-Founder News In a notable development for shareholders of the German biotechnology giant, Citi has revised its financial outlook for BioNTech SE (NASDAQ: BNTX) . The financial services firm announced it is lowering its price target on the company's shares to $130 from $145 , a reduction of approximately 10%. Des

$BNTX The Founders Left. The Pipeline Didn't.This morning BioNTech dropped a bombshell. Co-founders Prof. Ugur Sahin and Prof. Özlem Türeci, the two scientists who built the mRNA platform that produced the world's first approved COVID-19 vaccine, announced they are leaving the company by end of 2026 to start a new independent mRNA-focused bi

by ConnectmyCurrency

Biontech: Vaccine stock breaking out is a warning sign !After a sideways consolidation for the past year, biontech is now showing signs of a major breakout. Charts always predict the news so we should expect some unfortunate global news very soon

05:34

by markethunter888

1/7/26 - BNTX: new BUY mechanical trading signal.1/7/26 - BNTX: new BUY signal chosen by a rules based, mechanical trading system. BNTX - BUY Stop Loss @ 91.11 Entry BUY @ 100.08 Target Profit @ 113.80 Analysis: Higher timeframe: Prices have stayed above the lower channel line of the ATR (Average True Range) Keltner Channel and reversed. High

Spring coiling up For the last 3-4 months, a bullish triangle has formed for biontech which has a bias to break to the upside. This stock was a big beneficiary of the last pandemic so it's safe to assume something similar is going to happen again.

03:44

by markethunter888

BNTX Long Trade Setup!📈 🚀 Price breaking trendline resistance—bullish momentum building 📊 Entry: $106.00 ✅ | Stop: $104.92 🛑 Target: $109.97 🎯 — watching for clean breakout 🔼 #BNTX #LongTrade #TechnicalAnalysis #TradingView #StockMarket

by ProfittoPath

Long Thesis on BioNTech SE Post-Earnings BioNTech SE presents a compelling long opportunity following its latest earnings report. The company continues to expand beyond COVID-19 vaccines, with a strong pipeline in personalized mRNA cancer therapies, infectious disease vaccines (HIV, tuberculosis, malaria), and autoimmunity treatments. With

BNTX BioN Tech Options Ahead of Earnings Analyzing the options chain and the chart patterns of BNTX BioN Tech prior to the earnings report this week, I would consider purchasing the $115usd strike price Calls with an expiration date of 2025-9-19, for a premium of approximately $17.40. If these options prove to be profitable prior to the ea

See all ideas

Technicals

Summarizing what the indicators are suggesting.

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

An aggregate view of professional's ratings.

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Seasonals

Displays a symbol's price movements over previous years to identify recurring trends.